Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Vasogen-- VAS on TSE -- Ignore unavailable to you. Want to Upgrade?

To: Stephen O who wrote (298)	7/26/2005 4:05:55 PM
From: Pluvia	Read Replies (2) \| Respond to of 377

If a new process produces dramatic results against inflammation, then the FDA will be under intense media pressure and medical community pressure to approve. poppycock. you might have a shred of argument if inflamation were a life threatening disease. but it's not. vasogen's other problem is, others with similar drugs have better results with the same diseases, can increase their dosing and, can identify specifically what's in their drug. while vasogen lingers in fda limbo trying to re-engineer their equipment so they can demonstrate what's in their drug, others will leapfrog vasogen & bolton. jmo